National Pharmacy Association (NPA) - News updates

Certain pages on this news feed are only available to NPA members and hence requires members to log-in accordingly

MEDICAL DEVICE ALERT – FreeStyle Libre flash glucose sensor

MEDICAL DEVICE ALERT Ref: MDA/2019/003 29 January 2019 FreeStyle Libre flash glucose sensor (Manufactured by Abbott)   A medical device alert has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for FreeStyle Libre flash glucose sensor. Patients who have experienced an immune response (skin reactions) to the sensor adhesive are using creams, patches or sprays. However, as such barrier methods have not been tested by the manufacturer, there is a potential for such products to affect the performance of the device.   Action to take Identify any patients experiencing skin reactions – this can include blistering, erythema and itching Consider if it is suitable for these patients to continue using the FreeStyle Libre flash glucose sensor – community pharmacy teams can refer such patients to the patient’s diabetes clinic/GP Consider an alternative blood glucose monitoring system   All adverse reactions need to be reported to the local incident reporting system and/or national incident reporting authority, as appropriate: England and Wales: Yellow Card website or Yellow Card App available on iOS devices and Android devices Northern Ireland: Northern Ireland Adverse Incident Centre (NIAIC) online form Scotland: Yellow Card website, Yellow Card App available on iOS devices and Android devices, or Incident Reporting and Investigation Centre (IRIC) (email iric@nhs.net to request a webform account)   Further information can be found on the MHRA section on the GOV.UK website.…

NHS England launching ‘Pharmacy Advice’ campaign

The ‘Pharmacy Advice’ campaign is part of NHS England’s overarching brand ‘Help Us Help You’ and will commence on February 4. The initiative will help to build the public’s trust and confidence in community pharmacists and the pharmacy team as providers of care, and ensure minor illnesses such as coughs, colds, tummy troubles and aches and pains are effectively managed in the right place. A printed set of branded resources will be sent to all community pharmacies in England, with delivery being made week commencing 28 January 2019. The pack will include a double-sided window sticker, wobblers, poster, information cards and a dispenser. The outer packaging will be clearly labelled with a green, NHS branded sticker (pictured). The NHS encourages community pharmacies to make the most of these resource by: Prominently displaying the materials in your pharmacy, in the window and alongside relevant over-the-counter products Using the information card to remind your customers to visit your pharmacy next time they need clinical advice about a minor health concern Ensuring all staff members are briefed ahead of the campaign to ensure that they are fully aware and, where appropriate, are ready to offer clinical advice for people with everyday minor health concerns.…

Class 2 medicines recall – Action within 48 hours – Irbesartan tablets 150mg and 300mg (Macleods Pharma UK Limited)

DRUG ALERT Class 2 medicines recall – Action within 48 hours Ref: EL (19)A/02 Date 24 January 2019 Irbesartan tablets 150mg and 300mg (Manufactured by Macleods Pharma UK Limited ) PL 34771/0079 (150mg) PL 34771/0080 (300mg)   A Class 2 medicines recall has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for certain batches of Irbesartan tablets 150mg and 300mg as follows:   Irbesartan tablets 150mg PL 34771/0079 Batch number Expiry date Pack size Date of first distribution EIZ807A July 2021 1 x 28 21/11/2018     Irbesartan tablets 300mg PL 34771/0080 Batch number Expiry date Pack size Date of first distribution EIA1813A July 2021 1 x 28 31/10/2018 EIA1811A July 2021 1 x 28 31/10/2018   The medicines recall is a precautionary measure that has been put into place due to potential contamination of the affected batches with N-nitrosodiethylamine (NDEA).   Further information can be found on the MHRA section on the GOV.UK website.…

NHS flu service 2019/20 – recommended flu vaccines and ordering (England)

NHS England has issued updated flu vaccine recommendations for the NHS flu service 2019/20, following on from their previous correspondence in November 2018. Based on the updated information, the table below lists the currently licensed flu vaccines available in the UK, detailing those recommended and reimbursed, and where ordering should be considered, for the NHS flu service for the 2019/20 season. Type of vaccine Licensed in the UK? Recommended for the NHS flu service 2019/20? Reimbursed for use in the NHS flu service 2019/20? Consider ordering for the NHS flu service 2019/20? Standard egg-cultured quadrivalent inactivated vaccine (QIVe) — will continue to be recommended for individuals 18-64 years of age, in clinical at-risk, or other, eligible groups Yes Yes Yes Yes Adjuvanted trivalent inactivated vaccine (aTIV) — will continue to be recommended for individuals 65 years of age and over Yes Yes Yes Yes Cell-grown quadrivalent vaccine (QIVc), Flucelvax® Tetra — licensed for use in individuals 9 years of age and over Yes Yes Yes Yes High-dose trivalent vaccine (TIV-HD) — JCVI also advised as equally suitable for use in those aged 65 years and over Yes NO NO NO   Flu vaccine ordering for 2019/20 flu season Taking into NHS England’s recommendations, you can consider ordering the following current licensed vaccines for the NHS flu service 2019/20: aTIV QIVc QIVe   IMPORTANT: The high-dose trivalent vaccine (TIV-HD) will not be commissioned or reimbursed for the NHS flu service 2019/20 Brand information is not currently available – NPA will update its members as it becomes so Further information from the Joint Committee on Vaccination and Immunisation (JCVI) is available in the NHS England letter on this matter – this includes the suitability of each flu vaccine in different age groups.…

National Pharmacy Association Board meeting – January 2019

The Board discussed next steps on the NHS Long Term Plan. References in the plan to medicines, workforce, urgent care and prevention are all areas inherently in our sector’s sphere of interest. There is also a strong emphasis on care close to home, which we need to translate into concrete opportunities for community pharmacy. The NHS is planning for the next decade, but many pharmacies are currently managing only month-by-month, because of overwhelming pressures on their funding and rising medicines costs. A new, multi-year, funding settlement for community pharmacies in England is needed, to give pharmacy owners the confidence to invest in services that will meet the priorities described in the long term plan. The NHS Plan is to a large extent a framework for commissioning at a local level, so a key challenge for the sector is to improve pharmacy engagement and collaboration locally. This is a very significant issue, and we’ll no doubt return to it many times in future.…

Community Pharmacy Living Well Service SOP (NI)

The NPA welcomes the Health and Social Care Board (HSCB) announcement that the Community Pharmacy Living Well Service will be available through participating pharmacies from April 2019. We encourage all members to complete necessary preparations for the delivery of the service and claim the preparatory grant of £500 by submitting their contract to the relevant Business Support Integrated Care Office by 31 January 2019. To assist participating pharmacies in their preparations, the NPA has published a standard operating procedure (SOP) for the Living Well Service.   For further information on this or any other query, please contact the NPA Pharmacy Services team on 01727 891 800 or email pharmacyservices@npa.co.uk.  Produced by the NPA Pharmacy Services team January 2019.…

Urgent QP reminder – have you met your NHS website profile and WES gateway criteria?

This is an urgent reminder that community pharmacies in England must fulfill all of the Quality Payments Scheme Gateway Criteria for the 15 February 2019 review point, otherwise you will not be eligible to claim Quality Payments for the Quality Criteria you have met. Over 2,000 contractors are currently at risk of losing out on quality payments because they are not meeting the NHS website gateway criterion Urgent actions required: NHS website profile criterion There are three sections of the NHS profile and they must all be updated / validated — opening times, facilities and services. You must update/validate your pharmacy’s NHS website profile between 3 December 2018 00.00 and 15 February 2019 23.59 Even if one or more sections are correct, you must still log into your pharmacy’s profile and validate it If one or more sections are not correct, you must update the information Distance-selling pharmacies need to ensure they have emailed NHS Business Services Authority Provider Assurance Team as required.…

Price Concessions – January 2019: updated

Drug (pack size) Price concession Allopurinol tablets 100mg (28) £1.70 Allopurinol  tablets 300mg (28) £3.68 Amiloride tablets 5mg (28) -NEW £10.20 Brimonidine eye drops 0.2% (5ml) – NEW £3.03 Bumetanide tablets 1mg (28) -NEW £1.95 Carvedilol tablets 3.125mg (28) – NEW £0.86 Carvedilol tablets 6.25mg (28) – NEW £0.90 Carvedilol tablets 25mg (28) – NEW £1.38 Co-careldopa  tablets 25mg/100mg (100) £10.69 Diamorphine powder for solution for injection ampoules 10mg (5) £16.56 Diamorphine powder for solution for injection ampoules 30mg (5) £16.52 Dosulepin capsules 25mg (28) – NEW £3.00 Dosulepin  tablets 75mg (28) £11.00 Fluoxetine capsules 20mg (30) – NEW £1.05 Furosemide  tablets 20mg (28) £1.25 Furosemide tablets 40mg (28) £2.21 Glyceryl trinitrate pump sublingual spray 400micrograms/dose (200 dose) – NEW £2.15 Hydroxocobalamin solution for injection ampoules 1mg/1ml (5) -NEW £9.70 Ibandronic acid 50mg tablets (28) £54.22 Latanoprost eye drops 50micrograms/ml  (2.5ml) £7.95 Lercanidipine tablets 10mg (28) – NEW £2.78 Levetiracetam oral solution sugar free 100mg/ml (300ml) – NEW £17.50 Lofepramine tablets 70mg (56) – NEW £17.20 Losartan  tablets 25mg (28) £5.27 Losartan tablets 50mg (28) £4.50 Losartan  tablets 100mg (28) £6.95 Metronidazole  tablets 200mg (21) £2.70 Naproxen tablets 250mg (28) – NEW £6.30 Naproxen  gastro-resistant tablets 500mg (56) £18.01 Nebivolol  tablets 2.5mg(28) £15.85 Nortriptyline tablets 10mg (100) £8.00 Propranolol tablets 80mg (56) – NEW £2.30 Quetiapine tablets 25mg (60) – NEW £4.50 Quetiapine  tablets 150mg (60) £6.60 Quetiapine tablets 300mg (60) – NEW £13.00 Ramipril tablets 2.5mg (28) £4.15 Ramipril tablets 5mg (28) £4.15 Ramipril tablets 10mg (28) – NEW £4.49 Risperidone  tablets 500microgram (20) £2.72 Risperidone tablets 2mg (60) £21.00 Risperidone  tablets 3mg (60) £24.95 Risperidone  tablets 4mg (60) £31.88 Sodium valproate gastro resistant tablets 200mg (100) £6.25 Sodium valproate gastro-resistant tablets 500mg (100) £17.50 Sodium valproate oral solution sugar free 200mg/5ml (300ml) £7.00 Tadalafil tablets 5mg  (28) £23.71 Telmisartan tablets 20mg (28) £3.80 Telmisartan  tablets (28) 40mg £6.94 Temazepam tablets 10mg (28) – NEW £1.46 Valsartan capsules 40mg (28) £4.49 Valsartan capsules 80mg (28) – NEW £7.25 Valsartan capsules 160mg (28) – NEW £9.53 Valsartan/Hydrochlorothiazide tablets 160mg/12.5mg £4.17    …

NHS England issue fresh ‘no deal’ Brexit guidance

To ensure that pharmacists are best placed to provide advice to their patients on the supply of medicines to the NHS in the event of a ‘no deal’ EU exit, Dr Ridge has set out a summary of the work underway across government and the NHS:   Medicine Supply Assessment: The government has undertaken a comprehensive assessment of medicines supply to identify products that have a manufacturing touch point in the EU or wider European Economic Area (EEA) countries.   Six Week Stockpile: DHSC has received very good engagement from industry on developing a six-week stockpile of prescription only medicines and pharmacy medicines to ensure supply for patients is maintained across the NHS. DHSC has also secured contract agreements for additional warehouse space for stockpiled medicines, including ambient, refrigerated and controlled drug storage.   Alternative Transport Routes: Government has reviewed transport routes for all medicines and plans are being developed with industry for re-routing where necessary.…

Expressions of interest for ORIEL 2020-2021 are now open